The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
Open accessAbstract
Advanced Breast Cancer (ABC) comprises both locally advanced breast cancer (LABC) and metastatic breast cancer (MBC) [1]. Although treatable, MBC remains virtually an incurable disease with a median overall survival (OS) of ∼3years and a 5-year survival of only ∼25% [2, 3]. The MBC Decade Report [2] shows that progress has been slow in terms of improved outcomes, quality of life (QoL), awareness and information regarding ABC. More recently, some studies seem to indicate an improvement in OS, mostly due to advances in human epidermal growth factor receptor 2 (HER2)-positive ABC [4–6].
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Robson, M., Im, S.-A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Li, W., Tung, N., Armstrong, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706450 · Cited by 3,294
Self-citationPalbociclib and letrozole in advanced breast cancer
Finn, R. S., Martin, M., Rugo, H. S., Jones, S., Im, S.-A., Gelmon, K., Harbeck, N., Lipatov, O. N., Walshe, J. M., Moulder, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607303 · Cited by 3,007
Self-citationRibociclib as first-line therapy for HR-positive, advanced breast cancer
Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y.-S., Sonke, G. S., Paluch-Shimon, S., Campone, M., Blackwell, K. L., André, F., Winer, E. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609709 · Cited by 2,039
Self-citation3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
Cardoso, F., Costa, A., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G., Biganzoli, L., Cardoso, M. J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw544 · Cited by 2,033
Self-citationFinn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71159-3 · Cited by 1,900
Cristofanilli, M., Turner, N. C., Bondarenko, I., Ro, J., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00613-0 · Cited by 1,827
Self-citationSledge, G. W., Toi, M., Neven, P., Sohn, J., Inoue, K., Pivot, X., Burdaeva, O., Okera, M., Masuda, N., Kaufman, P. A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.7585 · Cited by 1,680 · cited 1×
“In the second-line setting, their use has been associated with a 6–7 months progression-free survival (PFS) benefit [33, 34] and an HRQoL improvement [35, 36], and hence their ESMO-MCBS score is 4.”
BackgroundSelf-citationLoren, A. W., Mangu, P. B., Beck, L. N., Brennan, L., Magdalinski, A. J., Partridge, A. H., Quinn, G., Wallace, W. H., & Oktay, K. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.2678 · Cited by 1,611
Le Tourneau, C., Delord, J.-P., Gonçalves, A., Gavoille, C., Dubot, C., Isambert, N., Campone, M., Trédan, O., Massiani, M.-A., Mauborgne, C., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00188-6 · Cited by 1,137
Swain, S. M., Kim, S.-B., Cortés, J., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.-M., Schneeweiss, A., Knott, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70130-x · Cited by 1,006 · cited 1×
“With the publication of the CLEOPATRA trial [45] results showing a substantial OS benefit, a non-data-driven protocol amendment was made to change the primary endpoint to PFS, in agreement with the regulatory authorities.”
MethodSelf-citationPeccatori, F. A., Azim, H. A., Orecchia, R., Hoekstra, H. J., Pavlidis, N., Kesic, V., & Pentheroudakis, G. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt199 · Cited by 790
Gucalp, A., Tolaney, S., Isakoff, S. J., Ingle, J. N., Liu, M. C., Carey, L. A., Blackwell, K., Rugo, H., Nabell, L., Forero, A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3327 · Cited by 749
Self-citationLevin, V. A., Bidaut, L., Hou, P., Kumar, A. J., Wefel, J. S., Bekele, B. N., Prabhu, S., Loghin, M., Gilbert, M. R., & Jackson, E. F. (2011) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.12.061 · Cited by 729
Bachelot, T., Bourgier, C., Cropet, C., Ray-Coquard, I., Ferrero, J.-M., Freyer, G., Abadie-Lacourtoisie, S., Eymard, J.-C., Debled, M., Spaëth, D., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.0708 · Cited by 703
Dickler, M. N., Tolaney, S. M., Rugo, H. S., Cortés, J., Diéras, V., Patt, D., Wildiers, H., Hudis, C. A., O'Shaughnessy, J., Zamora, E., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0754 · Cited by 676
Self-citationESMO-magnitude of clinical benefit scale version 1.1
Cherny, N. I., Dafni, U., Bogaerts, J., Latino, N. J., Pentheroudakis, G., Douillard, J.-Y., Tabernero, J., Zielinski, C., Piccart, M. J., & de Vries, E. G. E. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx310 · Cited by 641
Dykewicz, C. A. (2001) · Clinical Infectious Diseases · doi:10.1086/321805 · Cited by 636
Robertson, J. F. R., Bondarenko, I. M., Trishkina, E., Dvorkin, M., Panasci, L., Manikhas, A., Shparyk, Y., Cardona-Huerta, S., Cheung, K.-L., Philco-Salas, M. J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)32389-3 · Cited by 582
Piccart, M., Hortobagyi, G. N., Campone, M., Pritchard, K. I., Lebrun, F., Ito, Y., Noguchi, S., Perez, A., Rugo, H. S., Deleu, I., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu456 · Cited by 574 · cited 1×
“Combination of an endocrine agent (AI, tamoxifen or fulvestrant) with everolimus has shown a PFS benefit, albeit without a statistically significant OS benefit [40, 41] in the second-line setting and, more recently, also in the first-line setting [42], and is an available option for patients previously exposed to ET.”
BackgroundSelf-citationRoila, F., Molassiotis, A., Herrstedt, J., Aapro, M., Gralla, R. J., Bruera, E., Clark-Snow, R. A., Dupuis, L. L., Einhorn, L. H., Feyer, P., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw270 · Cited by 574
Self-citationESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)
Cardoso, F., Costa, A., Norton, L., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Biganzoli, L., Blackwell, K. L., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu385 · Cited by 540 · cited 9×
“As already extensively discussed in previous editions, the main recommendation for these patients is the induction of OFS/OFA, to which an additional endocrine agent should be added [1, 11].”
BackgroundInfluentialSelf-citationEnzalutamide for the Treatment of Androgen Receptor–Expressing Triple-Negative Breast Cancer
Traina, T. A., Miller, K., Yardley, D. A., Eakle, J., Schwartzberg, L. S., O’Shaughnessy, J., Gradishar, W., Schmid, P., Winer, E., Kelly, C., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.3495 · Cited by 530
Self-citationAndré, F., Bachelot, T., Commo, F., Campone, M., Arnedos, M., Dieras, V., Lacroix-Triki, M., Lacroix, L., Cohen, P., Gentien, D., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70611-9 · Cited by 404
Self-citationPaluch-Shimon, S., Cardoso, F., Sessa, C., Balmana, J., Cardoso, M. J., Gilbert, F., & Senkus, E. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw327 · Cited by 399
Self-citationESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)
Cardoso, F., Costa, A., Norton, L., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Biganzoli, L., Blackwell, K. L., et al. (2014) · The Breast · doi:10.1016/j.breast.2014.08.009 · Cited by 338
Self-citationGlobal analysis of advanced/metastatic breast cancer: decade report (2005-2015)
Cardoso, F., Spence, D., Mertz, S., Corneliussen-James, D., Sabelko, K., Gralow, J., Cardoso, M.-J., Peccatori, F., Paonessa, D., Benares, A., et al. (2018) · The Breast · doi:10.1016/j.breast.2018.03.002 · Cited by 324 · cited 2×
“The MBC Decade Report [2] shows that progress has been slow in terms of improved outcomes, quality of life (QoL), awareness and information regarding ABC.”
BackgroundSelf-citation1st International consensus guidelines for advanced breast cancer (ABC 1)
Cardoso, F., Costa, A., Norton, L., Cameron, D., Cufer, T., Fallowfield, L., Francis, P., Gligorov, J., Kyriakides, S., Lin, N., et al. (2012) · The Breast · doi:10.1016/j.breast.2012.03.003 · Cited by 303
Self-citationPeterson, D. E., Boers-Doets, C. B., Bensadoun, R. J., & Herrstedt, J. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv202 · Cited by 299
Self-citationA Comprehensive Definition for Integrative Oncology
Witt, C. M., Balneaves, L. G., Cardoso, M. J., Cohen, L., Greenlee, H., Johnstone, P., Kücük, Ö., Mailman, J., & Mao, J. J. (2017) · JNCI Monographs · doi:10.1093/jncimonographs/lgx012 · Cited by 296
Self-citationBonnefoi, H., Grellety, T., Tredan, O., Saghatchian, M., Dalenc, F., Mailliez, A., L'Haridon, T., Cottu, P., Abadie-Lacourtoisie, S., You, B., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw067 · Cited by 283
(2013) · Fertility and Sterility · doi:10.1016/j.fertnstert.2013.08.041 · Cited by 277
Verma, S., Bartlett, C. H., Schnell, P., DeMichele, A. M., Loi, S., Ro, J., Colleoni, M., Iwata, H., Harbeck, N., Cristofanilli, M., et al. (2016) · The Oncologist · doi:10.1634/theoncologist.2016-0097 · Cited by 249
Self-citation3rd ESO–ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3)
Cardoso, F., Costa, A., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G., Biganzoli, L., Cardoso, M. J., et al. (2017) · The Breast · doi:10.1016/j.breast.2016.10.001 · Cited by 228
Self-citationRugo, H. S., Seneviratne, L., Beck, J. T., Glaspy, J. A., Peguero, J. A., Pluard, T. J., Dhillon, N., Hwang, L. C., Nangia, C., Mayer, I. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30109-2 · Cited by 226
Self-citationLiedtke, C., Thill, M., & on behalf of the AGO Breast Committee (2016) · Breast Care · doi:10.1159/000446941 · Cited by 189
Initial experience with bevacizumab treatment for biopsy confirmed cerebral radiation necrosis
Torcuator, R., Zuniga, R., Mohan, Y. S., Rock, J., Doyle, T., Anderson, J., Gutierrez, J., Ryu, S., Jain, R., Rosenblum, M., et al. (2009) · Journal of Neuro-Oncology · doi:10.1007/s11060-009-9801-z · Cited by 188
Improved survival in metastatic breast cancer 1985-2016
Sundquist, M., Brudin, L., & Tejler, G. (2017) · The Breast · doi:10.1016/j.breast.2016.10.005 · Cited by 188
Harbeck, N., Iyer, S., Turner, N., Cristofanilli, M., Ro, J., André, F., Loi, S., Verma, S., Iwata, H., Bhattacharyya, H., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw139 · Cited by 176
Self-citationRugo, H. S., Dieras, V. C., Gelmon, K. A., Finn, R. S., Slamon, D. J., Martín, M., Neven, P., Shparyk, Y. V., Mori, A., Lu, D. R., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy012 · Cited by 160
Self-citationMalmgren, J. A., Mayer, M., Atwood, M. K., & Kaplan, H. G. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4529-5 · Cited by 147
Self-citationPritchard, K. I., Burris, H. A., Ito, Y., Rugo, H. S., Dakhil, S. R., Hortobágyi, G. N., Campone, M., Csőszi, T., Baselga, J. M., Puttawibul, P., et al. (2013) · Clinical Breast Cancer · doi:10.1016/j.clbc.2013.08.011 · Cited by 112
Self-citationAn analysis of radiation necrosis of the central nervous system treated with bevacizumab
Tye, K. E., Engelhard, H. H., Slavin, K. V., Nicholas, M. K., Chmura, S. J., Kwok, Y., Ho, D. S., Weichselbaum, R. R., & Koshy, M. (2014) · Journal of Neuro-Oncology · doi:10.1007/s11060-014-1391-8 · Cited by 99
Delishaj, D., Ursino, S., Pasqualetti, F., Cristaudo, A., Cosottini, M., Fabrini, M. G., & Paiar, F. (2017) · Journal of Clinical Medicine Research · doi:10.14740/jocmr2936e · Cited by 94
European Breast Cancer Conference manifesto on breast centres/units
Cardoso, F., Cataliotti, L., Costa, A., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2016.10.023 · Cited by 79
Self-citationGómez, P., & Lacouture, M. E. (2011) · The Oncologist · doi:10.1634/theoncologist.2011-0115 · Cited by 73
Royce, M., Bachelot, T., Villanueva, C., Özgüroğlu, M., Azevedo, S. J., Cruz, F. M., Debled, M., Hegg, R., Toyama, T., Falkson, C. I., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.0060 · Cited by 71
Self-citationReversal of cerebral radiation necrosis with bevacizumab treatment in 17 Chinese patients
Wang, Y., Pan, L., Sheng, X., Mao, Y. Q., Yao, Y., Wang, E., Zhang, N., & Dai, J. (2012) · European journal of medical research · doi:10.1186/2047-783x-17-25 · Cited by 68
Fietz, T., Tesch, H., Rauh, J., Boller, E., Kruggel, L., Jänicke, M., & Marschner, N. (2017) · The Breast · doi:10.1016/j.breast.2017.05.014 · Cited by 65
Hortobágyi, G. N., Stemmer, S. M., Burris, H. A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.1038 · Cited by 55
Tolaney, S. M., Lin, N., Thornton, D., Klise, S. R., Costigan, T. M., Turner, P. K., & Anders, C. K. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.1019 · Cited by 54
Hölzel, D., Eckel, R., Bauerfeind, I., Baier, B., Beck, T., Braun, M., Ettl, J., Hamann, U., Kiechle, M. B., Mahner, S., et al. (2017) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-017-2428-0 · Cited by 52
Self-citationKobayashi, K., Ito, Y., Matsuura, M., Fukada, I., Horii, R., Takahashi, S., Akiyama, F., Iwase, T., Hozumi, Y., Yasuda, Y., et al. (2016) · Surgery Today · doi:10.1007/s00595-015-1252-x · Cited by 45
Noguchi, S., Kim, H. J., Anita, J., Parmar, V. V., Sato, N., Wang, H.-C., Lokejaroenlarb, S., Isidro, J., Kim, K. S., Itoh, Y., et al. (2015) · Breast Cancer · doi:10.1007/s12282-015-0637-4 · Cited by 43
Witt, C. M., & Cardoso, M. J. (2016) · The Breast · doi:10.1016/j.breast.2016.04.012 · Cited by 42
Self-citationGenetic testing in women with breast cancer: implications for treatment
Paterson, R. J., & Phillips, K. (2017) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2017.1374175 · Cited by 19
Goetz, M. P., Toi, M., Klise, S. R., Frenzel, M., Bourayou, N., & Leo, A. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.tps624 · Cited by 16
Verma, S., O’Shaughnessy, J., Burris, H. A., Campone, M., Alba, E., Chandiwana, D., Manson, S. C., Sutradhar, S., Monaco, M., & Janni, W. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.1020 · Cited by 16
Editorial: Why are guidelines not followed in clinical practice?
Cardoso, F., & Gennari, A. (2016) · The Breast · doi:10.1016/j.breast.2016.12.004 · Cited by 6
Self-citationHarbeck, N., Iyer, S. S., Bhattacharyya, H., et al. (2017) · The Breast · doi:10.1016/s0960-9776(17)30684-7 · Cited by 5
Self-citation
Research works printed but not linked: 14
- Masuda, 2011, Monthly versus 3-monthly goserelin acetate treatment in pre-menopausal patients with estrogen receptor-positive early breast cancer, Breast Cancer Res Treat, 126, 443, 10.1007/s10549-010-1332-y · doi:10.1007/s10549-010-1332-y
- Tabernero, 2017, Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers, ESMO Open, 1, e000142, 10.1136/esmoopen-2016-000142 · doi:10.1136/esmoopen-2016-000142
- Walsh, 2017, Oncofertility: fertile ground for conflict between patient autonomy and medical values, Oncologist, 22, 860, 10.1634/theoncologist.2016-0373 · doi:10.1634/theoncologist.2016-0373
- Tripathy, 2018, First-line ribociclib vs placebo with goserelin and tamoxifen or a non-steroidal aromatase inhibitor in premenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the randomized phase III MONALEESA-7 trial, Cancer Res, 78
- Di Leo, 2017, 236O_PR. MONARCH 3: abemaciclib as initial therapy for patients with HR+/HER2- advanced breast cancer, Ann Oncol, 28, mdx440.008
- Rugo, 2017, Abstract P6-11-12: subgroup analysis by prior treatment and disease burden in MONARCH 1: a phase 2 study of monotherapy abemaciclib, a CDK4 & 6 inhibitor, in patients with HR+/HER2- metastatic breast cancer (MBC) following chemotherapy, Cancer Res, 77, 11
- Gradishar, 2017, Phase III study of lapatinib (L) plus trastuzumab (T) and aromatase inhibitor (AI) vs T+AI vs L+AI in postmenopausal women (PMW) with HER2+, HR+ metastatic breast cancer (MBC): ALTERNATIVE, J Clin Oncol, 35, 1004, 10.1200/JCO.2017.35.15_suppl.1004 · doi:10.1200/jco.2017.35.15_suppl.1004
- Valencia, 2017, The role of genetic testing in patients with breast cancer: a review, JAMA Surg, 152, 589, 10.1001/jamasurg.2017.0552 · doi:10.1001/jamasurg.2017.0552
- Litton, 2015, A phase 3, open-label, randomized, parallel, 2-arm international study of the oral PARP inhibitor talazoparib (BMN 673) in BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA), J Clin Oncol, 33, TPS1107, 10.1200/jco.2015.33.15_suppl.tps1107 · doi:10.1200/jco.2015.33.15_suppl.tps1107
- Boothe, 2013, Bevacizumab as a treatment for radiation necrosis of brain metastases post stereotactic radiosurgery, Neuro Oncol, 15, 1257, 10.1093/neuonc/not085 · doi:10.1093/neuonc/not085
- Bollet, 2012, Preoperative radio-chemotherapy in early breast cancer patients: long-term results of a phase II trial, Radiother Oncol, 102, 82, 10.1016/j.radonc.2011.08.017 · doi:10.1016/j.radonc.2011.08.017
- Coles, 2017, Preoperative radiation therapy: the ‘new’ targeted breast cancer treatment?, Eur J Cancer, 78, 116, 10.1016/j.ejca.2017.03.027 · doi:10.1016/j.ejca.2017.03.027
- Bun, 2018, Symptom management: the utility of regional cooling for hand-foot syndrome induced by pegylated liposomal doxorubicin in ovarian cancer, Support Care Cancer, 26, 2161, 10.1007/s00520-018-4054-z · DOI
- Oliveira, 2017, OR135—effect of exercise on cardiovascular fitness and quality of life outcomes in advanced breast cancer patients, Breast, 36, S71, 10.1016/S0960-9776(17)30754-3 · doi:10.1016/s0960-9776(17)30754-3
Cited by
Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer
Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Hegg, R., Im, S.-A., Shaw Wright, G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809615 · Cited by 4,350
Self-citationHarbeck, N., Penault-Llorca, F., Cortes, J., Gnant, M., Houssami, N., Poortmans, P., Ruddy, K., Tsang, J., & Cardoso, F. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0111-2 · Cited by 3,024
Self-citationAlpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
André, F., Ciruelos, E., Rubovszky, G., Campone, M., Loibl, S., Rugo, H. S., Iwata, H., Conte, P., Mayer, I. A., Kaufman, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1813904 · Cited by 2,622
Self-citation5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M. S., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G. S., Biganzoli, L., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.09.010 · Cited by 1,369
Self-citationTucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer
Murthy, R. K., Loi, S., Okines, A., Paplomata, E., Hamilton, E., Hurvitz, S. A., Lin, N. U., Borges, V., Abramson, V., Anders, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1914609 · Cited by 1,326
Self-citation
Metadata
- Authors
- Cardoso, F., Senkus, E., Costa, A., Papadopoulos, E., Aapro, M., André, F., Harbeck, N., Aguilar Lopez, B., Barrios, C. H., Bergh, J., Biganzoli, L., Boers-Doets, C. B., Cardoso, M. J., Carey, L. A., Cortés, J., Curigliano, G., Diéras, V., El Saghir, N. S., Eniu, A., Fallowfield, L., Francis, P. A., Gelmon, K., Johnston, S. R. D., Kaufman, B., Koppikar, S., Krop, I. E., Mayer, M., Nakigudde, G., Offersen, B. V., Ohno, S., Pagani, O., Paluch-Shimon, S., Penault-Llorca, F., Prat, A., Rugo, H. S., Sledge, G. W., Spence, D., Thomssen, C., Vorobiof, D. A., Xu, B., Norton, L., & Winer, E. P.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2018-08
- Volume
- 29
- Issue
- 8
- Pages
- 1634-1657
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W4239051461
- Cited by
- 1,171
- References
- 59
- FWCI
- 48.09
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 450 d)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.